<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04610528</url>
  </required_header>
  <id_info>
    <org_study_id>SOLTI-1805</org_study_id>
    <secondary_id>2019-004964-23</secondary_id>
    <nct_id>NCT04610528</nct_id>
  </id_info>
  <brief_title>A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression</brief_title>
  <acronym>TOT-HER3</acronym>
  <official_title>A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SOLTI Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SOLTI Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial design This is a prospective, multicenter, single-arm, window-of-opportunity study&#xD;
      evaluating the biological effect of patritumab deruxtecan in treatment naïve patients with&#xD;
      HR-positive/HER2-negative early breast cancer, whose primary tumors are ≥1 cm by ultrasound&#xD;
      evaluation. Patients will be enrolled in four cohorts according to the mRNA-based ERBB3&#xD;
      expression by central assessment. The objective of the study is to evaluate biological&#xD;
      activity of patritumab deruxtecan in patients with treatment naïve early breast cancer. The&#xD;
      primary endpoint is CelTIL score after one single-dose of U3-1402. A translational research&#xD;
      plan is also included to provide biological information and to evaluate secondary and&#xD;
      exploratory objectives of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 22, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CelTIL score</measure>
    <time_frame>baseline and after one dose of U3-1402 at Cycle 1 Day 21</time_frame>
    <description>Mean change in CelTIL score per central assessment in paired samples.&#xD;
CelTIL score = -0.8 × tumor cellularity (in %) + 1.3 × TILs (in %). The minimum and maximum unscaled CelTIL scores will be -80 and 130. This unscaled CelTIL score will then be scaled to reflect a range from 0 to 100 points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CelTIL score</measure>
    <time_frame>baseline and after one dose of U3-1402 at Cycle 1 Day 21</time_frame>
    <description>Mean change in CelTIL score per central assessment in paired samples for each ERBB3 cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ERBB3 levels vs. CelTIL score</measure>
    <time_frame>baseline and after one dose of U3-1402 at Cycle 1 Day 21</time_frame>
    <description>ERBB3 mRNA baseline levels and changes in CelTIL score for all patients and for each ERBB3 cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HER3 IHC vs. CelTIL score</measure>
    <time_frame>baseline and after one dose of U3-1402 at Cycle 1 Day 21</time_frame>
    <description>HER3 IHC baseline levels and changes in CelTIL score for all patients and for each ERBB3 cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PAM50 intrinsic subtypes vs. CelTIL score</measure>
    <time_frame>baseline and after one dose of U3-1402 at Cycle 1 Day 21</time_frame>
    <description>changes in CelTIL across the four PAM50 intrinsic subtypes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Cell Cycle Arrest (CCCA)</measure>
    <time_frame>baseline and after one dose of U3-1402 at Cycle 1 Day 21</time_frame>
    <description>determined per central assessment by IHC Ki67&lt; 2.7%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ERBB3 mRNA expression vs. HER3 IHC</measure>
    <time_frame>baseline</time_frame>
    <description>Correlation coefficients between both biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability</measure>
    <time_frame>through study completion, an average of 65 days each patient</time_frame>
    <description>Type, incidence, severity (as graded by the NCI CTCAE v. 5.0), seriousness and attribution to the study medications of AEs and any laboratory abnormalities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of HER3 expression.</measure>
    <time_frame>t baseline, at Day 3-Day 7 (optional), Cycle 1 Day 21</time_frame>
    <description>HER3 expression</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>U3-1402</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>U3-1402 is an antibody drug conjugate (ADC) comprising a recombinant fully human anti-human epidermal growth factor receptor (HER) 3 immunoglobulin G1 (IgG1) monoclonal antibody (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a). MAAA-1181a is released after internalization and leads to apoptosis of the target tumor cells by the inhibition of topoisomerase I</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>U3 1402</intervention_name>
    <description>U3-1402 is an antibody drug conjugate (ADC) comprising a recombinant fully human anti-human epidermal growth factor receptor (HER) 3 immunoglobulin G1 (IgG1) monoclonal antibody (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a)</description>
    <arm_group_label>U3-1402</arm_group_label>
    <other_name>Patritumab Deruxtecan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written ICF for all study procedures according to local regulatory requirements prior&#xD;
             to beginning specific protocol procedures.&#xD;
&#xD;
          2. Premenopausal or postmenopausal women and men, age ≥ 18 years.&#xD;
&#xD;
          3. ECOG Performance Status 0 - 1.&#xD;
&#xD;
          4. Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast&#xD;
             untreated and recently diagnosed, with all the following characteristics:&#xD;
&#xD;
               -  At least one lesion that can be measured in at least 1 dimension with ≥ 1 cm in&#xD;
                  largest diameter measured by ultrasound.&#xD;
&#xD;
               -  Absence of distant metastasis (M0) as determined by institutional practice.&#xD;
&#xD;
               -  In the case of a multifocal tumor (defined as the presence of two or more foci of&#xD;
                  cancer within the same breast quadrant), the largest lesion must be ≥ 1 cm and&#xD;
                  designated the &quot;target&quot; lesion for all subsequent tumor evaluations and biopsies.&#xD;
&#xD;
          5. Patient must have biopsiable disease.&#xD;
&#xD;
          6. Estrogen (ER)-positive and/or Progesterone (PgR)-positive and HER2-negative tumor by&#xD;
             the most recent American Society of Clinical Oncology - College of American&#xD;
             Pathologists (ASCO-CAP) guidelines: ER and PgR defined as IHC nuclear staining &gt;1% and&#xD;
             HER2 negative locally assessed.&#xD;
&#xD;
          7. Ki67% ≥ 10% locally assessed (Dowsset et al. Journal of the National Cancer Institute,&#xD;
             103 (22), 1656-1664. 2011).&#xD;
&#xD;
          8. Available pre-treatment FFPE core needle biopsy evaluable for PAM50 and ERBB3 mRNA&#xD;
             expression. Minimal sample requirements are to have at least 2 tumor cylinders with a&#xD;
             minimal tissue surface of 10 mm2 tissue, containing at least 50% tumor cells and&#xD;
             having enough tissue to do at least 20 cuts of 4 μm each. Macrodissection is allowed&#xD;
             when needed. If archival tissue is either insufficient or unavailable, a new biopsy&#xD;
             from the pretreated tumor must be obtained. Patients whose tumor tissue is not&#xD;
             evaluable for ERBB3 expression central testing are not eligible.&#xD;
&#xD;
          9. Baseline LVEF ≥ 50% measured by echocardiography (ECHO) or Multiple Gate Acquisition&#xD;
             (MUGA) scan&#xD;
&#xD;
         10. Adequate organ function, as determined by the following laboratory tests prior to&#xD;
             randomization:&#xD;
&#xD;
               -  Hematological&#xD;
&#xD;
                    -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
                    -  Platelet count ≥ 100 x 109/L&#xD;
&#xD;
                    -  Hemoglobin ≥ 9 g/dL (red blood cell transfusion and/or erythropoietin&#xD;
                       allowed)&#xD;
&#xD;
               -  Renal&#xD;
&#xD;
                  o Serum creatinine ≤ 1.5 x upper limit of normal (ULN), or 24-hour creatinine&#xD;
                  clearance ≥ 60 mL/min for subject with creatinine levels &gt; 1.5 x ULN. (Note:&#xD;
                  Creatinine clearance does not need to be determined if the baseline serum&#xD;
                  creatinine is within normal limits. Creatinine clearance should be calculated per&#xD;
                  institutional standard).&#xD;
&#xD;
               -  Hepatic&#xD;
&#xD;
                    -  Serum bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for a subject with&#xD;
                       total bilirubin level &gt; 1.5 x ULN&#xD;
&#xD;
                    -  Aspartate aminotransferase (AST) ≤ 3 x ULN&#xD;
&#xD;
                    -  Alanine aminotransferase (ALT) ≤ 3 x ULN&#xD;
&#xD;
                    -  Coagulation International normalization ratio (INR) or prothrombin time (PT)&#xD;
                       ≤ 1.5 x ULN&#xD;
&#xD;
                    -  Partial thromboplastin time (PTT) or activated PTT (aPTT) ≤ 1.5 x ULN&#xD;
&#xD;
         11. Absence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule; those&#xD;
             conditions should be discussed with the patient before registration in the trial.&#xD;
&#xD;
         12. Female subject of childbearing potential should have a negative urine or serum&#xD;
             pregnancy test within 7 days prior to enrollment. If urine pregnancy test is positive&#xD;
             or cannot be confirmed as negative, a serum pregnancy test will be required. Pregnancy&#xD;
             testing does not need to be pursued in patients who are judged as postmenopausal&#xD;
             before randomization, as determined by local practice, or who have undergone bilateral&#xD;
             oophorectomy, total hysterectomy, or bilateral tubal ligation. Women of childbearing&#xD;
             potential randomized to the treatment must use adequate contraception for the duration&#xD;
             of protocol treatment and after 7 months after the study drug administration (see&#xD;
             Appendix B).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inoperable locally advanced or inflammatory (i.e., inoperable Stage III) breast&#xD;
             cancer.&#xD;
&#xD;
          2. Metastatic (Stage IV) breast cancer.&#xD;
&#xD;
          3. Bilateral invasive breast cancer.&#xD;
&#xD;
          4. Patients in whom a primary tumor excisional biopsy was performed.&#xD;
&#xD;
          5. Any prior treatment for primary actual invasive breast cancer.&#xD;
&#xD;
          6. Prior treatment with a HER3 antibody, topoisomerase I inhibitor, with an ADC which&#xD;
             consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g., DS-8201)&#xD;
             and with a govitecan derivative (e.g., IMMU-132).&#xD;
&#xD;
          7. Medical history of symptomatic congestive heart failure (New York Heart Association&#xD;
             classes II-IV) or serious cardiac arrhythmia requiring treatment; myocardial&#xD;
             infarction within 6 months prior to randomization or unstable angina.&#xD;
&#xD;
          8. QT interval corrected using Fridericia's formula to &gt; 450 millisecond (ms) in males&#xD;
             and &gt; 470 ms in females.&#xD;
&#xD;
          9. Any factors that increase the risk of corrected QT (QTc) interval prolongation or risk&#xD;
             of arrhythmic events, such as congenital long QT syndrome, family history of long QT&#xD;
             syndrome, or unexplained sudden death under 40 years of age in first-degree relatives.&#xD;
&#xD;
         10. Medical history of clinically significant lung diseases (e.g., interstitial pneumonia,&#xD;
             pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or who are&#xD;
             suspected to have these diseases by imaging at screening period.&#xD;
&#xD;
         11. Clinically significant corneal disease.&#xD;
&#xD;
         12. Major surgical procedure or significant traumatic injury within 28 days prior to&#xD;
             randomization.&#xD;
&#xD;
         13. Assessment by the investigator to be unable or unwilling to comply with the&#xD;
             requirements of the protocol.&#xD;
&#xD;
         14. History of other malignancy within the last 3 years, except for appropriately treated&#xD;
             carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer,&#xD;
             or other malignancies with an expected curative outcome.&#xD;
&#xD;
         15. Current severe, uncontrolled systemic disease (e.g. clinically significant&#xD;
             cardiovascular, pulmonary or metabolic disease; wound healing disorders; ulcers; bone&#xD;
             fractures).&#xD;
&#xD;
         16. Concurrent, serious, uncontrolled infections or current known infection with HIV or&#xD;
             active hepatitis B and/or hepatitis C.&#xD;
&#xD;
         17. History of significant co-morbidities that, in the judgment of the investigator, may&#xD;
             interfere with the conduction of the study, the evaluation of response, or with ICF.&#xD;
&#xD;
         18. Known hypersensitivity to either the drug substance components (including an antibody,&#xD;
             a drug-linker, or a topoisomerase I inhibitor) or inactive ingredients in the drug&#xD;
             product or history of severe hypersensitivity reactions to other monoclonal&#xD;
             antibodies.&#xD;
&#xD;
         19. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses&#xD;
             including, but not limited to, any underlying pulmonary disorder (i.e. pulmonary&#xD;
             emboli within three months of the study enrollment, severe asthma, severe COPD,&#xD;
             restrictive lung disease, pleural effusion etc.), and any autoimmune, connective&#xD;
             tissue or inflammatory disorders with potential pulmonary involvement (i.e. rheumatoid&#xD;
             arthritis, Sjögren's syndrome, sarcoidosis etc.), or prior pneumonectomy.&#xD;
&#xD;
         20. Has unresolved toxicities from previous anticancer therapy, defined as toxicities&#xD;
             (other than alopecia) not yet resolved to National Cancer Institute Common Terminology&#xD;
             Criteria for Adverse Events (NCI-CTCAE) version 5.0, grade ≤1 or baseline. Subjects&#xD;
             with chronic grade 2 toxicities may be eligible per the discretion of the&#xD;
             Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Juan Manuel Ferrero Cafiero</last_name>
    <phone>609691648</phone>
    <email>ferrerocafiero.juanmanuel@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ICO Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mireia Margeli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia Hospitalet</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sonia Pernas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Tenerife</city>
        <state>Islas Canarias</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Josefina Cruz Jurado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juan Antonio Guerra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliveira</last_name>
    </contact>
    <investigator>
      <last_name>Mafalda Oliveira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aleix Prat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncológico Clara Campal (CIOCC)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ana Luna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pablo Tolosa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Javier Salvador Bofil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juan Miguel Cejalvo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>her3</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Patritumab deruxtecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

